Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 10535 [2019-05389]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 55 / Thursday, March 21, 2019 / Notices
DEPARTMENT OF JUSTICE
Drug
code
Controlled substance
Schedule
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 22, 2019. Such persons
may also file a written request for a
hearing on the application on or before
April 22, 2019.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on August
17, 2018, Fisher Clinical Services, Inc.,
7554 Schantz Road, Allentown,
Pennsylvania 18106 applied to be
registered as an importer of the
following basic classes of controlled
substances:
amozie on DSK9F9SC42PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
18:27 Mar 20, 2019
Jkt 247001
Psilocybin ......................
Methylphenidate ............
Levorphanol ...................
Noroxymorphone ...........
Tapentadol .....................
7437
1724
9220
9668
9780
I
II
II
II
II
The company plans to import the
listed controlled substances for clinical
trials.
Dated: March 6, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–05389 Filed 3–20–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1121–0317]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested;
Reinstatement, With Change, of a
Previously Approved Collection for
Which Approval Has Expired: 2020/
2022 Identity Theft Supplement (ITS)
Bureau of Justice Statistics,
Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Department of Justice
(DOJ), Office of Justice Programs,
Bureau of Justice Statistics, will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until May
20, 2019.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Erika Harrell, Statistician, Bureau of
Justice Statistics, 810 Seventh Street
NW, Washington, DC 20531 (email:
Erika.Harrell@usdoj.gov; telephone:
202–307–0758).
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
SUMMARY:
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
10535
functions of the Bureau of Justice
Statistics, including whether the
information will have practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Reinstatement of the Identity Theft
Supplement, with changes, a previously
approved collection for which approval
has expired.
(2) The Title of the Form/Collection:
2020/2022 Identity Theft Supplement.
The agency form number, if any, and
the applicable component of the
Department sponsoring the collection:
The form number for the questionnaire
is ITS–1. The applicable component
within the Department of Justice is the
Bureau of Justice Statistics, in the Office
of Justice Programs.
(3) Affected public who will be asked
or required to respond, as well as a brief
abstract: Respondents will be persons
16 years or older living in households
located throughout the United States
sampled for the National Crime
Victimization Survey (NCVS). The ITS
will be conducted as a supplement to
the NCVS in all sample households for
a six (6) month period. The ITS is
primarily an effort to measure the
prevalence of identity theft among
persons, the characteristics of identity
theft victims, and patterns of reporting
to the police, credit bureaus, and other
authorities. The ITS was also designed
to collect important characteristics of
identity theft such as how the victim’s
personal information was obtained; the
physical, emotional and financial
impact on victims; offender information;
and the measures people take to avoid
or minimize their risk of becoming an
identity theft victim. BJS plans to
publish this information in reports and
reference it when responding to queries
from the U.S. Congress, Executive Office
of the President, the U.S. Supreme
Court, state officials, international
organizations, researchers, students, the
E:\FR\FM\21MRN1.SGM
21MRN1
]]>Agencies
[Federal Register Volume 84, Number 55 (Thursday, March 21, 2019)]
[Notices]
[Page 10535]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-05389]
[[Page 10535]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Fisher Clinical
Services, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before April 22, 2019. Such
persons may also file a written request for a hearing on the
application on or before April 22, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on August
17, 2018, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown,
Pennsylvania 18106 applied to be registered as an importer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Psilocybin............................. 7437 I
Methylphenidate........................ 1724 II
Levorphanol............................ 9220 II
Noroxymorphone......................... 9668 II
Tapentadol............................. 9780 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
clinical trials.
Dated: March 6, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-05389 Filed 3-20-19; 8:45 am]
BILLING CODE 4410-09-P
